Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 13/20 | 0.47 |
| ▸ | EGFR | P00533 | 4/20 | 0.47 |
| ▸ | MKNK2 | Q9HBH9 | 6/20 | 0.44 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.38 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24569523 | 1.00 | ERBB2 (0.47) | ERBB2EGFRMKNK2ERBB3ERBB4 | |
| SCHEMBL29888038 | 0.84 | EGFR (0.56) | ERBB2EGFRMKNK2ERBB3ERBB4 | |
| SCHEMBL24569414 | 0.84 | EGFR (0.56) | ERBB2EGFRMKNK2ERBB3ERBB4 | |
| SCHEMBL29888184 | 0.81 | ERBB2 (0.46) | ERBB2EGFRMKNK2ERBB3ERBB4 | |
| SCHEMBL24569467 | 0.81 | ERBB2 (0.46) | ERBB2EGFRMKNK2ERBB3ERBB4 | |
| SCHEMBL29887923 | 0.81 | ERBB2 (0.51) | ERBB2EGFRMKNK2ERBB3ERBB4 | |
| SCHEMBL31476048 | 0.81 | ERBB2 (0.45) | ERBB2EGFRMKNK2ERBB3ERBB4 | |
| SCHEMBL24570016 | 0.80 | ERBB2 (0.43) | ERBB2EGFR | |
| SCHEMBL25432634 | 0.79 | ERBB2 (0.56) | ERBB2EGFR | |
| SCHEMBL30575966 | 0.79 | ERBB2 (0.56) | ERBB2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4267137-A1 | LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 | Enliven Inc. (US) | 2023-11-01 | — | — | EP | disclosed |
| WO-2022140769-A1 | LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN THERAPEUTICS, INC. (US) | 2022-06-30 | — | — | WO | disclosed |